pharmacies, doctors' offices, and community centers.

In the Fall of 2005, the Spanish language campaign was pilot tested by 5 state health departments that receive funding from CDC for their arthritis programs. CDC will eventually disseminate these materials to all 36 CDC-funded states. The 5 preliminary pilot tests focused on reach and exposure; a more thorough evaluation is necessary to assess impact of the campaign. This information will be used to guide the public health practice of the 36 state arthritis programs and their partners.

CDC will conduct an evaluation of the impact of the Spanish language health communications campaign on the exercise/physical activity-related attitudes, beliefs, and behaviors among the target audience of Spanish-speaking people with arthritis. There are no costs to the respondents other than their time.

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
Screening Survey	12,000	1	2/60	400
Telephone Survey	2,500	1	15/60	625
Total				1,025

Dated: March 28, 2007.

Joan F. Karr,

Acting Reports Clearance Officer, Centers for Disease Control and Prevention.

[FR Doc. E7–6276 Filed 4–3–07; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Technical Support for Birth Defects and Developmental Disabilities Prevention Education Efforts, Contract Solicitation Number (CSN) 2006–N–08835

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned SEP:

Time and Date: 12 p.m.–3 p.m., April 30, 2007 (Closed).

Place: Teleconference, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Atlanta, GA 30333.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to CSN 2006–N–08835, ''Technical Support for Birth Defects and Developmental Disabilities Prevention Education Efforts.''

For Further Information Contact: Christine Morrison, Ph.D., Scientific Review Administrator, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop D72, Atlanta, GA 30333, Telephone 404.639.3098.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: March 28, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7–6270 Filed 4–3–07; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Preparation for International Conference on Harmonisation Meetings in Brussels, Belgium; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting entitled ''Preparation for ICH Meetings in Brussels, Belgium'' to provide information and receive comments on the International Conference on Harmonisation (ICH) as well as the upcoming meetings in Brussels, Belgium. The topics to be discussed are the topics for discussion at the forthcoming ICH steering committee meeting. The purpose of the meeting is to solicit public input prior to the next steering committee and expert working groups meetings in Brussels, Belgium May 5–10, 2007, at which discussion of the topics underway and the future of ICH will continue.

Date and Time: The meeting will be held on Friday April 6, 2007, from 3:30 p.m. to 5 p.m.

Location: The meeting will be held at 5600 Fishers Lane, third floor, Conference Room G, Rockville, MD 20857. For security reasons, all attendees are asked to arrive no later than 3:20 p.m., as you will be escorted from the front entrance of 5600 Fishers Lane to Conference Room G.

Contact Person: Michelle Limoli, Office of the Commissioner (HFG–1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–0908, e-mail: *michelle.limoli@fda.hhs.gov*, FAX: 301–827–0003.

Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, and fax number), written material, and requests to make oral presentations, to the contact person by April 5, 2007.

If you need special accommodations due to a disability, please contact Michelle Limoli as soon as possible.

SUPPLEMENTARY INFORMATION: The ICH was established in 1990 as a joint regulatory/industry project to improve, through harmonization, the efficiency of the process for developing and registering new medicinal products in Europe, Japan, and the United States without compromising the regulatory obligations of safety and effectiveness.

In recent years, many important initiatives have been undertaken by regulatory authorities and industry

associations to promote international harmonization of regulatory requirements. FDA has participated in many meetings designed to enhance harmonization and is committed to seeking scientifically-based harmonized technical procedures for pharmaceutical development. One of the goals of harmonization is to identify and then reduce differences in technical requirements for medical product development among regulatory agencies. ICH was organized to provide an opportunity for harmonization initiatives to be developed with input from both regulatory and industry representatives. ICH is concerned with harmonization among three regions: The European Union, Japan, and the United States. The six ICH sponsors are the European Commission; the European Federation of Pharmaceutical Industries Associations; the Japanese Ministry of Health, Labor and Welfare; the Japanese Pharmaceutical Manufacturers Association; the Centers for Drug Evaluation and Research and Biologics Evaluation and Research, FDA; and the Pharmaceutical Research and Manufacturers of America. The ICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation of Pharmaceutical Manufacturers Associations. The ICH steering committee includes representatives from each of the ICH sponsors and Health Canada, the European Free Trade Area, and the World Health Organization. The ICH process has achieved significant harmonization of the technical requirements for the approval of pharmaceuticals for human use in the three ICH regions.

The current ICH process and structure can be found at the following Web site: *http://www.ich.org*.

Interested persons may present data, information, or views orally or in writing, on issues pending at the public meeting. Oral presentations from the public will be scheduled between approximately 4:30 p.m. and 5 p.m. Time allotted for oral presentations may be limited to 10 minutes. Those desiring to make oral presentations should notify the contact person by April 5, 2007, and submit a brief statement of the general nature of the evidence or arguments they which to present, the names and addresses, phone number, fax, and e-mail of proposed participants, and an indication of the approximate time requested to make their presentation.

The agenda for the public meeting will be made available via the Internet at *http://www.fda.gov/cder/meeting/ICH_20060508.htm*.

Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 6–30, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.

Dated: March 28, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 07–1633 Filed 3–29–07; 3:56 pm]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

List of Recipients of Indian Health Scholarships Under the Indian Health Scholarship Program

The regulations governing Indian Health Care Improvement Act Programs (Pub. L. 94–437) provide at 42 CFR 136.334 that the Indian Health Service shall publish annually in the **Federal Register** a list of recipients of Indian Health Scholarships, including the name of each recipient, school and Tribal affiliation, if applicable. These scholarships were awarded under the authority of Sections 103 and 104 of the Indian Health Care Improvement Act, 25 U.S.C. 1613–1613a, as amended by the Indian Health Care Amendments of 1988, Pub. L. 100–713.

The following is a list of Indian Health Scholarship Recipients funded under Sections 103 and 104 for Fiscal Year 2006:

Adams, Staci Brook, Northern Oklahoma College, Ponca Tribe of Indians of Oklahoma.

Ahenakew, Carol Marie, Walla Walla College, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana.

Albers, Travis Alan, University of Mary, Turtle Mountain Band of Chippewa Indians of North Dakota.

Allen, Bryan Zachary, Southwestern Oklahoma State University, Choctaw Nation of Oklahoma.

Arredondo, Michael Howard, University of Minnesota/Duluth, Eastern Shawnee Tribe of Oklahoma.

Augare-Deal, Rael, University of Kansas, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana.

Azure, Donna Rae, Turtle Mountain Community College, Turtle Mountain Band of Chippewa Indians of North Dakota.

Azure, Krysten Ross, University of North Dakota, Sisseton-Wahpeton Sioux Tribe of the Lake Traverse Reservation, South Dakota.

Babbitt, Jaime Lynn, Indiana University, Navajo Nation, Arizona, New Mexico& Utah.

Baker, Allison Marie, University of North Dakota, Three Affiliated Tribes of the Fort Berthold Reservation, North Dakota.

Baker, Laiel Inez, University of North Dakota, Three Affiliated Tribes of the Fort Berthold Reservation, North Dakota.

Baker, Valerie, University of New Mexico, Navajo Nation, Arizona, New Mexico & Utah.

Bales-Poirot, Deidre Leann, University of Missouri/Columbia, Eastern Shawnee Tribe of Oklahoma.

Banteah, Melinda Erika, University of New Mexico/Albuquerque, Zuni Tribe of the Zuni Reservation, New Mexico.

Barnett, Stephanie Deann, University of Pittsburgh, Cherokee Nation, Oklahoma.

Barrett, Courtney Paige, University of Oklahoma, Seminole Nation of Oklahoma.

Bayer, Amelia Dianne, University of New Mexico, Choctaw Nation of Oklahoma.

Beals, Bryan James, University of North Dakota, Muscogee (Creek) Nation, Oklahoma.

Beardslee, Amber Rochelle, The University of Puget Sound, Central Council of Tlingit & Haida Indian Tribes.

Beaver, Aaron Don, University of Oklahoma, Choctaw Nation of Oklahoma.

Beaver, Allen Don, University of Oklahoma, Choctaw Nation of Oklahoma.

Bebeau, Shari Kaye, University of Minnesota, Minnesota Chippewa Tribe, Minnesota.

Becenti, Elton, New Mexico State University, Navajo Nation, Arizona, New Mexico & Utah.

Becker, Tischa Lee, University of New Mexico, Cherokee Nation, Oklahoma.

Begay, Melanie, University of New Mexico, Navajo Nation, Arizona, New Mexico & Utah.

Begay, Monica Calley, University of New Mexico/Albuquerque, Navajo Nation, Arizona, New Mexico & Utah.

Begay, Velda Ann, Arizona State University, Navajo Nation, Arizona, New Mexico & Utah.

Begaye, Adrienne Marie, University of Arizona, Navajo Nation, Arizona, New Mexico & Utah.

Begaye, Amelia June, University of New Mexico, Navajo Nation, Arizona, New Mexico & Utah.

Begaye, Julianna, University of New Mexico, Navajo Nation, Arizona, New Mexico & Utah.